Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome
✍ Scribed by C. Schneider; R. Gold; M. Schäfers; K.V. Toyka
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 162 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Mycophenolate mofetil 1.5 g daily (30 mg/kg body weight) was given to a patient with ankylosing spondylitis, ulcerative colitis, and severe refractory polymyositis after conventional treatment regimes had failed. No severe side effects occurred. Considerable improvement of clinical symptoms and electromyographic findings were seen within 6 months after the initiation of mycophenolate mofetil, allowing for tapering and discontinuation of methylprednisolone. Mycophenolate mofetil may be considered as an useful alternative in the treatment of polymyositis when standard therapeutic regimens fail. © 2002 John Wiley & Sons, Inc. Muscle Nerve 25: 286–288, 2002 DOI 10.1002/mus.10026
📜 SIMILAR VOLUMES
Wilms' tumor is a childhood nephroblastoma that is postulated to arise through the inactivation of a tumor suppressor gene by a two-hit mechanism. A candidate I I p I 3 Wilms' tumor gene, WTI. has been cloned and shown to encode a zinc finger protein. Patients with the WAGR syndrome (Wilms' tumor, a